MedPath

Efficacy and Safety of Teprenone in Patients With Acute Gastritis, Acute Gastric Lesion of Chronic Gastritis With Acute Exacerbation or Gastric Ulcer

Phase 4
Completed
Conditions
Acute Gastritis
Gastric Ulcer
Interventions
Registration Number
NCT01190657
Lead Sponsor
Eisai Co., Ltd.
Brief Summary

This is a self-controlled, open, multiple-center clinical trial.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
1184
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Selbex 50mg (14 days)Selbex-
Selbex 50mg (56 days)Selbex-
Primary Outcome Measures
NameTimeMethod
Endoscopic results of ulcer lesion56 days

Heal rate = (healed cases + significant improved cases)/total cases administered ×100 %

Total effective rate56 days.

Total effective rate = (healed cases + significant improved cases + effective cases)/total cases administered ×100 %.

Secondary Outcome Measures
NameTimeMethod
Symptoms improved level56 days

Trial Locations

Locations (26)

Chinese People's Liberation Army General Hospital of Beijing Military

🇨🇳

Beijing, China

Chongqing First People's Hospital

🇨🇳

Chongqing, China

The Second Affiliated Hospital of Chongqing Medical University

🇨🇳

Chongqing, China

Wuhan Union Hospital

🇨🇳

Hubei, China

Changsha Central Hospital

🇨🇳

Hunan, China

Hunan Provincial People's Hospital

🇨🇳

Hunan, China

Nanjing First Hospital

🇨🇳

Jiangsu, China

Nanjing General Hospital of Nanjing Military Command

🇨🇳

Jiangsu, China

The Second Affiliated Hospital of Nanjing Medical University

🇨🇳

Jiangsu, China

The Second Affiliated Hospital of Suzhou University

🇨🇳

Jiangsu, China

Scroll for more (16 remaining)
Chinese People's Liberation Army General Hospital of Beijing Military
🇨🇳Beijing, China

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.